Compare Amgen, Inc. (AMGN) vs United Parcel Service Inc (UPS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs United Parcel Service Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while United Parcel Service Inc trades at $112.5 (market cap $95.60B). The key difference: Amgen, Inc. is far larger — about 2.1× United Parcel Service Inc's market cap, and United Parcel Service Inc pays the higher dividend (5.83%). Which is the better fit depends on your goals.
| AMGN | UPS | |
|---|---|---|
Market Cap | $196.12B | $95.60B |
Sector | Health | Industrials |
52-Week High | $388.16 | $120.00 |
52-Week Low | $271.18 | $82.58 |
Enterprise Value | $241.41B | $118.46B |
Dividend Yield | 2.77% | 5.83% |
Volume | — | 2,288,643 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
UPS trades at $112.47, up 1.56% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 33.41% ROE and 5.94% net margin, though revenue has declined from $100.3B in 2022 to $88.66B in 2025. Recent news highlights a $48M investment in healthcare logistics and competition concerns from Amazon's logistics expansion.
Outlook is mixed: valuation appears reasonable with a P/E of 18.2, and analysts give a $112 consensus target, but revenue pressure and competitive threats pose risks. The dividend remains supported by solid cash flow, but growth depends on successful execution in a challenging environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
